Opexa Therapeutics (OPXA) 0.71 $OPXA
Update: Takeaways From Opexa's Plan To Dilute Shareholders
Trevor Lowenthal - at Seeking Alpha - Wed Jan 28, 12:26PM CST
OPXA: 0.71 (-0.03)
Opexa Therapeutics, Inc. Files Registration Statement for Rights Offering
Business Wire - Wed Jan 28, 5:05AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed rights offering of subscription rights to purchase units comprised of a share of Opexa common stock and warrants to purchase an additional share of Opexa common stock. Holders of Opexa's common stock and holders of Series L warrants as described below on the record date for the rights offering would be eligible to participate.
OPXA: 0.71 (-0.03)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.71 (-0.03), ATNM: 3.60 (-0.29), AKER: 3.50 (+0.20), CGIX: 7.07 (unch)
Small Cap Profiles: OPXA, NEWC, TRNS, MLER
ACCESSWIRE - Thu Dec 11, 9:35AM CST
WHITEFISH, MT / ACCESSWIRE / December 11, 2014 /
TRNS: 9.54 (+0.02), BIIB: 391.66 (-0.45), OPXA: 0.71 (-0.03), SNY: 49.42 (+0.82)
Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 18, 8:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.
OPXA: 0.71 (-0.03)
Pieris Appoints Michael Richman as Supervisory Board Member
Marketwired - Wed Nov 12, 9:15AM CST
Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
OPXA: 0.71 (-0.03)
Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
Business Wire - Tue Nov 11, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.
OPXA: 0.71 (-0.03)
Update: Opexa Q3 Earnings, Buyout Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 4:52AM CST
OPXA: 0.71 (-0.03), MRK: 58.81 (-0.07)
Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 3:02PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company's recent corporate developments.
OPXA: 0.71 (-0.03)
Opexa reports November 6
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:50AM CST
OPXA: 0.71 (-0.03)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 6th.
OPXA: 0.71 (-0.03)
Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS
Business Wire - Wed Oct 22, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.
OPXA: 0.71 (-0.03)
Opexa Therapeutics to Present at Cleveland Clinic's 12th Annual Medical Innovation Summit
Business Wire - Mon Oct 20, 8:03AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been invited to present at the Cleveland Clinic's 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
OPXA: 0.71 (-0.03)
Opexa Therapeutics Announces Analyst and Investor Event
Business Wire - Thu Oct 02, 1:09PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
OPXA: 0.71 (-0.03)
Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent
Business Wire - Mon Sep 29, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa's intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
OPXA: 0.71 (-0.03)
Investors look to Lighten Up on Shares of Opexa Therapeutics, Shares Down 7.6% (OPXA)
Comtex SmarTrend(R) - Thu Sep 25, 11:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's worst performing penny stocks, down 7.6% to $0.85 on 1.3x average daily volume. Thus far today, Opexa Therapeutics has traded 316,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -1.5%) and underperformed the S&P 500 (-7.6% to the S&P's -1.5%) during today's trading.
OPXA: 0.71 (-0.03)
Opexa Therapeutics Up 5.6%, Shares Break Through Resistance (OPXA)
Comtex SmarTrend(R) - Thu Sep 18, 10:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's best performing low-priced stocks, up 5.6% to $1.14 on 1.1x average daily volume. Opexa Therapeutics has traded 211,000 shares thus far today, vs. average volume of 200,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 0.5%) and outperformed the S&P 500 (5.6% to the S&P's 0.4%) during today's trading.
OPXA: 0.71 (-0.03)
Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock
Business Wire - Tue Sep 16, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014. The termination results from an assessment by Opexa's management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa's stockholders. As a result of such termination, no shares will be sold pursuant to the offering.
OPXA: 0.71 (-0.03)
Update: Takeaways From Opexa's Plan To Dilute Shareholders
Trevor Lowenthal - at Seeking Alpha - Wed Jan 28, 12:26PM CST
OPXA: 0.71 (-0.03)
Opexa Therapeutics, Inc. Files Registration Statement for Rights Offering
Business Wire - Wed Jan 28, 5:05AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed rights offering of subscription rights to purchase units comprised of a share of Opexa common stock and warrants to purchase an additional share of Opexa common stock. Holders of Opexa's common stock and holders of Series L warrants as described below on the record date for the rights offering would be eligible to participate.
OPXA: 0.71 (-0.03)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT. OPXA: 0.71 (-0.03), ATNM: 3.60 (-0.29), AKER: 3.50 (+0.20), CGIX: 7.07 (unch)
Small Cap Profiles: OPXA, NEWC, TRNS, MLER
ACCESSWIRE - Thu Dec 11, 9:35AM CST
WHITEFISH, MT / ACCESSWIRE / December 11, 2014 /
TRNS: 9.54 (+0.02), BIIB: 391.66 (-0.45), OPXA: 0.71 (-0.03), SNY: 49.42 (+0.82)
Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 18, 8:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.
OPXA: 0.71 (-0.03)
Pieris Appoints Michael Richman as Supervisory Board Member
Marketwired - Wed Nov 12, 9:15AM CST
Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
OPXA: 0.71 (-0.03)
Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
Business Wire - Tue Nov 11, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.
OPXA: 0.71 (-0.03)
Update: Opexa Q3 Earnings, Buyout Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 4:52AM CST
OPXA: 0.71 (-0.03), MRK: 58.81 (-0.07)
Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 3:02PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company's recent corporate developments.
OPXA: 0.71 (-0.03)
Opexa reports November 6
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:50AM CST
OPXA: 0.71 (-0.03)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 6th.
OPXA: 0.71 (-0.03)
Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS
Business Wire - Wed Oct 22, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.
OPXA: 0.71 (-0.03)
Opexa Therapeutics to Present at Cleveland Clinic's 12th Annual Medical Innovation Summit
Business Wire - Mon Oct 20, 8:03AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been invited to present at the Cleveland Clinic's 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
OPXA: 0.71 (-0.03)
Opexa Therapeutics Announces Analyst and Investor Event
Business Wire - Thu Oct 02, 1:09PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
OPXA: 0.71 (-0.03)
Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent
Business Wire - Mon Sep 29, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa's intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
OPXA: 0.71 (-0.03)
Investors look to Lighten Up on Shares of Opexa Therapeutics, Shares Down 7.6% (OPXA)
Comtex SmarTrend(R) - Thu Sep 25, 11:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's worst performing penny stocks, down 7.6% to $0.85 on 1.3x average daily volume. Thus far today, Opexa Therapeutics has traded 316,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -1.5%) and underperformed the S&P 500 (-7.6% to the S&P's -1.5%) during today's trading.
OPXA: 0.71 (-0.03)
Opexa Therapeutics Up 5.6%, Shares Break Through Resistance (OPXA)
Comtex SmarTrend(R) - Thu Sep 18, 10:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's best performing low-priced stocks, up 5.6% to $1.14 on 1.1x average daily volume. Opexa Therapeutics has traded 211,000 shares thus far today, vs. average volume of 200,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 0.5%) and outperformed the S&P 500 (5.6% to the S&P's 0.4%) during today's trading.
OPXA: 0.71 (-0.03)
Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock
Business Wire - Tue Sep 16, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014. The termination results from an assessment by Opexa's management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa's stockholders. As a result of such termination, no shares will be sold pursuant to the offering.
OPXA: 0.71 (-0.03)
